Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
2020
PURPOSENCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile–driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with tumors harboring act...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
43
References
30
Citations
NaN
KQI